HALO stock forecast, quote, news & analysis
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies... Show more
Halozyme Therapeutics (HALO) Stock Analysis: ENHANZE Partnerships Fuel Growth Momentum
Key Takeaways
- Halozyme Therapeutics (HALO) has secured major collaborations with GSK and Oruka, expanding ENHANZE® and Hypercon™ technologies into oncology and psoriasis treatments.
- Stock trades near the middle of its 52-week range (47.50–82.22), with analysts maintaining a consensus "Buy" rating and average price target of $85.78.
- Recent AGM highlighted raised 2026 guidance, projecting royalty revenues over $1.13 billion and adjusted EBITDA of $1.125–1.205 billion.
- Q1 2026 earnings due May 11, with expectations for EPS of $1.54 and revenue growth of 35% year-over-year.
- Tickeron's Trending AI Robots offer tools with win rates up to 88% and annualized returns exceeding 100% for copy trading.
- Strong royalty-driven model supports long-term value amid biotech sector volatility.
Current Market Snapshot
Halozyme Therapeutics (HALO) stock has navigated recent trading sessions with resilience amid broader biotech fluctuations, maintaining a position within its established range. Bolstered by robust royalty streams from ENHANZE®-enabled drugs like Darzalex SC (subcutaneous formulation) and Vyvgart Hytrulo, the shares reflect investor confidence in the company's drug-delivery platform. Market capitalization stands at approximately $7.6 billion, with a forward P/E ratio underscoring growth potential. Recent sessions show balanced volume and sentiment, as partnerships and guidance updates counterbalance sector headwinds, positioning HALO for continued scrutiny ahead of quarterly results.
Trending AI Robots
Tickeron’s Trending AI Robots page features a curated selection of 25 top-performing bots from its library of over 350 AI trading bots that analyze thousands of tickers across diverse strategies, timeframes, and market conditions. These bots employ advanced Financial Learning Models (FLMs) to generate real-time signals for copy trading, emphasizing those excelling in today's volatile environment—such as semiconductors, industrials, and ETFs—with win rates from 51% to 88%, profit factors up to 11.7, and annualized returns spanning +23% to +285%. For instance, the Space Infrastructure bot (15-min timeframe) delivers +285% annualized returns at 72% win rate across five tickers, while others like GraniteShares 2x Long Alphabet achieve +136% at 69% win rate. Varying from swing trading to dip-buying, these bots adapt to short- and long-term horizons, offering risk-managed virtual agents or signal-only options. Explore Trending AI Robots to identify strategies aligning with current HALO market dynamics and enhance your trading edge.
Recent Developments Driving HALO Price Action
Halozyme Therapeutics has experienced measured price action in recent weeks, influenced by strategic partnerships, leadership updates, and reaffirmed growth trajectories, keeping shares stable around $64 despite biotech sector pressures. A pivotal catalyst emerged on May 7, 2026, when Halozyme announced a global collaboration and license agreement with GSK plc to apply its ENHANZE® technology—based on recombinant human hyaluronidase enzyme (rHuPH20)—to develop subcutaneous (SC) formulations for multiple oncology targets, marking the first ENHANZE® deal including antibody-drug conjugates (ADCs). GSK committed an upfront payment, milestones, and royalties, with the initial clinical trial slated for 2026; this bolstered sentiment around Halozyme's platform expansion into high-growth oncology, though shares dipped mildly (-1.75%) amid profit-taking.
Preceding this, on May 6, Halozyme's Hypercon™ subsidiary inked a global exclusive license with Oruka Therapeutics for its novel Hypercon™ delivery tech on ORKA-001, a psoriasis candidate, plus an option for another target—complete with upfronts, milestones, and royalties. This deal, building on positive Phase 2a data for ORKA-001, reinforced Halozyme's diversification beyond ENHANZE®, contributing to modest gains (+0.7%) as investors eyed pipeline potential.
At the May 7 Annual General Meeting (AGM), shareholders approved directors, executive pay, and auditors, while CEO Helen Torley highlighted 2025 execution—record $1.4 billion revenue—and raised 2026 guidance: total revenue $1.71–1.81 billion (23–30% YoY growth), royalties $1.13–1.17 billion (30–35% growth, hitting $1 billion milestone a year early), adjusted EBITDA $1.125–1.205 billion, and non-GAAP EPS $7.75–8.25. This update, driven by strong uptake of partners like Darzalex SC, Vyvgart Hytrulo, and Phesgo, offset prior Q4 2025 EPS miss and supported steady sentiment.
Earlier, on April 30, Halozyme appointed Darren Snellgrove as CFO, signaling leadership stability amid growth; analysts responded positively, with H.C. Wainwright lifting its target to $95 (Buy) and TD Cowen to $96. Consensus remains "Buy" (average target $85.78), reflecting royalty momentum. Q1 2026 earnings, set for May 11, anticipate EPS $1.54 (+39% YoY) and revenue $358–380 million (+35% YoY), with focus on partner sales. Macro factors like biotech funding and regulatory nods for SC biologics have aided, though litigation risks (e.g., Merck) linger. Overall, these events have anchored HALO's price, blending optimism with caution ahead of results.
2026 Outlook and Key Factors to Monitor
Halozyme enters 2026 with elevated guidance underscoring its royalty-centric model, projecting total revenues of $1.71–1.81 billion and royalties surpassing $1.13 billion, fueled by ENHANZE® partners like Janssen's Darzalex SC (multiple myeloma), argenx's Vyvgart Hytrulo (myasthenia gravis), and Roche's Phesgo (breast cancer). Adjusted EBITDA of $1.125–1.205 billion highlights margin expansion (prior ~78% gross), aided by operational efficiencies and ~$2 billion in five-year capital returns via repurchases.
Investors should track partner milestones, including GSK's 2026 oncology trial initiation and Oruka's Hypercon™-enabled psoriasis readout, alongside new deals leveraging ENHANZE® (10+ partners) and Hypercon™ platforms. Industry shifts toward SC delivery—improving patient convenience and adherence—position Halozyme favorably, but competition in drug-delivery tech and patent litigations (e.g., multi-year Merck dispute) pose risks. Regulatory approvals for co-formulated biologics, API manufacturing ramp-up post-Surf Bio acquisition, and biotech M&A (mergers and acquisitions) trends will influence trajectory. Cost controls amid R&D investments (~$60 million for Hypercon™) and share repurchase execution remain pivotal for EPS delivery.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Momentum Indicator for HALO turns negative, indicating new downward trend
HALO saw its Momentum Indicator move below the 0 level on June 17, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In of the 80 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for HALO turned negative on June 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HALO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
HALO broke above its upper Bollinger Band on June 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HALO advanced for three days, in of 323 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (37.313) is normal, around the industry mean (20.966). P/E Ratio (24.204) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). HALO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (5.624) is also within normal values, averaging (367.026).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets
Industry Biotechnology